Clinical Trial Update: A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

View source ↗

Summary

A long-term, post-marketing study to evaluate the immune response in patients treated with Palynziq for phenylketonuria, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• PALYNZIQ (PEGVALIASE-PQPZ)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria (PKU) | Status: RECRUITING